Integra LifeSciences (NASDAQ:IART) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Integra LifeSciences from “Buy” to “Hold.” The broader analyst consensus is “Reduce,” with one Buy, five Hold, and two Sell ratings and an average price target of $18.86.
• Integra lowered its 2026 revenue and EPS guidance following production interruptions and costs related to Cincinnati flooding. Full-year EPS guidance fell to $2.30–$2.40 from $2.40–$2.50.
• The company plans to launch a $600 million secured term loan to improve liquidity and refinance existing obligations, though the additional debt may increase borrowing costs and leverage. Shares opened at $12.68, down 21.2%.

Integra LifeSciences (NASDAQ:IART - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Truist Financial upgraded Integra LifeSciences to a "hold" rating in a report on Thursday. Citigroup reiterated a "neutral" rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. BMO Capital Markets started coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They set a "market perform" rating and a $19.00 price target for the company. Finally, Wells Fargo & Company lifted their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce" and an average target price of $18.86.

Integra LifeSciences Stock Down 21.2%

Shares of Integra LifeSciences stock opened at $12.68 on Friday. The company has a fifty day moving average price of $16.69 and a 200 day moving average price of $15.15. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The stock has a market cap of $986.12 million, a price-to-earnings ratio of -140.87, a price-to-earnings-growth ratio of 0.83 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts forecast that Integra LifeSciences will post 2.46 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

A number of hedge funds have recently made changes to their positions in IART. Paradigm Capital Management Inc. NY acquired a new stake in Integra LifeSciences in the second quarter valued at $61,766,000. Hsbc Holdings PLC acquired a new position in Integra LifeSciences during the 4th quarter worth $879,000. Bank of New York Mellon Corp bought a new stake in shares of Integra LifeSciences in the 2nd quarter worth about $8,723,000. Glenmede Trust Co. NA increased its position in shares of Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock worth $9,276,000 after purchasing an additional 211,774 shares during the last quarter. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Integra LifeSciences in the 1st quarter valued at about $280,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra expects to generate strong cash flow despite the disruption, while the proposed seven-year, $600 million Senior Secured Term Loan B could improve liquidity and refinance existing obligations. Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
• Neutral Sentiment: Preliminary third-quarter adjusted EPS guidance is $0.55-$0.59, broadly in line with the $0.56 analyst consensus, suggesting the immediate-quarter impact may be manageable. Truist also upgraded the shares to a “Hold,” indicating a more balanced view rather than a bullish recommendation. Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
• Negative Sentiment: Integra reduced its 2026 revenue forecast to $1.634 billion-$1.654 billion from $1.654 billion-$1.695 billion. Full-year EPS guidance was lowered to $2.30-$2.40 from $2.40-$2.50, below the $2.46 consensus estimate. The cuts reflect production interruptions and millions of dollars in costs associated with the Cincinnati flooding. Integra LifeSciences Lowers Revenue and Earnings Outlook for 2026
• Negative Sentiment: The $600 million debt refinancing may support operations, but it also raises concerns about borrowing costs and leverage, particularly as profitability is being reduced by the flood-related disruption. The combination of lower guidance, facility uncertainty and additional secured debt explains why IART shares have decreased sharply and traded at unusually high volume. Integra Lowers FY26 Forecast Following Cincinnati Flood; Plans $600M Debt Refinance

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.